Pediatric Epilepsy
A research team led by CURE Grantee Dr. Jeong Ho Lee identified a mutation in the BRAF gene that causes intrinsic epileptogenicity in pediatric brain tumors.
The purpose of the study is to evaluate the effect of stable co-administered oxcarbazepine (OXC), on the pharmacokinetics (PK), safety, tolerability of padsevonil (PSL) and the plasma PK of PSL metabolites, UCB1431322-000 and UCB1447499-000, in study participants with epilepsy compared with study participants co-medicated with stable doses of levetiracetam (LEV), lamotrigine (LTG) or brivaracetam (BRV) therapy.
The completion of this project should permit the unveiling of a new neuronal mechanism supporting the lack of conscious experience during absences and pave the way for new clinical non-invasive strategies to interrupt ongoing seizure activity.
Becoming familiar with this new language can enable you and your doctor to better communicate about your treatment options, triggers to avoid, and what to expect in the future.
Researchers have taken further steps toward developing a superior animal model of neurological conditions such as traumatic brain injury and epilepsy, according to a study of miniature pigs published in eNeuro. The results establish the pig as a promising preclinical research model for hippocampal-dependent human memory disorders.
Researchers say pigs are promising preclinical research models for hippocampal-dependent human memory disorders.
Supernus Pharmaceuticals said it has agreed to acquire Biscayne Neurotherapeutics for up to $185 million, in a deal that adds a Phase I epilepsy candidate to the buyer’s pipeline of treatments for central nervous system disorders.
The epilepsy candidate, which Supernus will rename SPN-817, uses a novel synthetic form of huperzine A, an acetyl cholinesterase inhibitor that according to the company has a novel mechanism of action and has shown anticonvulsant activity in preclinical models for partial seizures and Dravet Syndrome.
